These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 19657333)

  • 1. From trial and error to trial simulation. Part 1: the importance of model-based drug development for antidepressant drugs.
    Santen G; van Zwet E; Danhof M; Della Pasqua O
    Clin Pharmacol Ther; 2009 Sep; 86(3):248-54. PubMed ID: 19657333
    [TBL] [Abstract][Full Text] [Related]  

  • 2. From trial and error to trial simulation. Part 2: an appraisal of current beliefs in the design and analysis of clinical trials for antidepressant drugs.
    Santen G; Horrigan J; Danhof M; Della Pasqua O
    Clin Pharmacol Ther; 2009 Sep; 86(3):255-62. PubMed ID: 19675543
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modelling placebo response in depression trials using a longitudinal model with informative dropout.
    Gomeni R; Lavergne A; Merlo-Pich E
    Eur J Pharm Sci; 2009 Jan; 36(1):4-10. PubMed ID: 19041717
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Factors contributing to failed trials of new agents: can technology prevent some problems?
    Greist JH; Mundt JC; Kobak K
    J Clin Psychiatry; 2002; 63 Suppl 2():8-13. PubMed ID: 15453008
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A kinetic-pharmacodynamic model for clinical trial simulation of antidepressant action: application to clomipramine-lithium interaction.
    Gruwez B; Poirier MF; Dauphin A; Olié JP; Tod M
    Contemp Clin Trials; 2007 May; 28(3):276-87. PubMed ID: 17059901
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Using longitudinal data from a clinical trial in depression to assess the reliability of its outcome scales.
    Laenen A; Alonso A; Molenberghs G; Vangeneugden T; Mallinckrodt CH
    J Psychiatr Res; 2009 Apr; 43(7):730-8. PubMed ID: 18986657
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rating rater improvement: a method for estimating increased effect size and reduction of clinical trial costs.
    Cogger KO
    J Clin Psychopharmacol; 2007 Aug; 27(4):418-20. PubMed ID: 17632240
    [No Abstract]   [Full Text] [Related]  

  • 8. Goodness-of-fit tests for GEE modeling with binary responses.
    Barnhart HX; Williamson JM
    Biometrics; 1998 Jun; 54(2):720-9. PubMed ID: 9629652
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interpreting antidepressant clinical trials.
    Sussman N
    Ann Clin Psychiatry; 2007; 19(4):215-20. PubMed ID: 18058279
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Justifying a "fast acting" claim for antidepressant drugs.
    Overall JE
    Psychopharmacol Bull; 1995; 31(1):45-55. PubMed ID: 7675989
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimal design of clinical trials with computer simulation based on results of earlier trials, illustrated with a lipodystrophy trial in HIV patients.
    Abbas I; Rovira J; Casanovas J; Greenfield T
    J Biomed Inform; 2008 Dec; 41(6):1053-61. PubMed ID: 18534916
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Using CTS and PK-PD models to predict the effect of uncertainty about population parameters on clinical trial power].
    Zhu L; Shi X; Liu Y
    Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2009 Feb; 26(1):42-6, 62. PubMed ID: 19334551
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Multicenter trials in the treatment of depression: some methodological issues].
    Staner L; Moulart D; Mendlewicz J
    Encephale; 1998; 24(6):522-9. PubMed ID: 9949935
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comments on "Clinical trials of antidepressants: time to shift to a new model" by Dr Katz.
    Rickels K; Robinson DS
    J Clin Psychopharmacol; 2009 Apr; 29(2):197-8; author reply 198-9. PubMed ID: 19512995
    [No Abstract]   [Full Text] [Related]  

  • 15. Bayesian analysis of hierarchical pattern-mixture models for clinical trials data with attrition and comparisons to commonly used ad-hoc and model-based approaches.
    Demirtas H
    J Biopharm Stat; 2005; 15(3):383-402. PubMed ID: 15920887
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of treatment response in depression studies using a Bayesian parametric cure rate model.
    Santen G; Danhof M; Della Pasqua O
    J Psychiatr Res; 2008 Oct; 42(14):1189-97. PubMed ID: 18353370
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Classifying responders and non-responders; does it help when there is evidence of differentially responding patient groups?
    Boessen R; Groenwold RH; Knol MJ; Grobbee DE; Roes KC
    J Psychiatr Res; 2012 Sep; 46(9):1169-73. PubMed ID: 22658815
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A local influence sensitivity analysis for incomplete longitudinal depression data.
    Shen S; Beunckens C; Mallinckrodt C; Molenberghs G
    J Biopharm Stat; 2006 May; 16(3):365-84. PubMed ID: 16724491
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Generalizability of antidepressant efficacy trials.
    Zimmerman M; Posternak MA; Chelminski I
    Essent Psychopharmacol; 2004; 6(1):45-58. PubMed ID: 15612653
    [No Abstract]   [Full Text] [Related]  

  • 20. Validation by simulation of a clinical trial model using the standardized mean and variance criteria.
    Abbas I; Rovira J; Casanovas J
    J Biomed Inform; 2006 Dec; 39(6):687-96. PubMed ID: 16464642
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.